Trial Profile
A Phase I/II trial of Paclitaxel Micellar in patients with severe cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Oasmia Pharmaceutical; Vivesto
- 16 Mar 2019 Results published in the Advances in Therapy
- 11 Jun 2018 Results presented in the Oasmia Pharmaceutical AB media release.